{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:49:59Z","timestamp":1778071799526,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although evidence has emerged to suggest that YAP overexpression is a crucial factor for tumor progression and resistance to targeted drugs in multiple cancers, the miRNA-mediated YAP regulation is still unclear. Here we show that the novel miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP. Our data showed that the miR-550a-3-5p suppressed cell proliferation, metastasis, and tumor sphere formation through the direct inhibition of YAP and its oncogenic pathway in various cancer cell types. In addition, we showed that the YAP signature was associated with poor survival of colon cancer and identified an inverse correlation between miR-550a-3-5p and YAP in colon cancer tissues. Interestingly, this inverse correlation was regulated in a density-dependent manner. Furthermore, high levels of miR-550a-3-5p were associated with a good prognosis of esophageal cancer, which was suggestive of the clinical relevance of miR-550a-3-5p-mediated YAP regulation in multiple cancers. Importantly, we demonstrated that miR-550a-3-5p treatment sensitized vemurafenib-resistant colon and melanoma cells through YAP inhibition with reduced AKT activity. Moreover, the tumor-suppressive activity of miR-550a-3-5p and its sensitization effect for vemurafenib resistance were also observed in tumor xenograft models. Collectively, our data suggest that miR-550a-3-5p acts as a tumor suppressor through the targeting of oncogenic YAP and may be a new therapeutic tool for YAP-mediated BRAF inhibitor resistance in BRAF-mutant cancer cells.<\/jats:p>","DOI":"10.1038\/s41419-018-0698-3","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T08:48:41Z","timestamp":1527583721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP"],"prefix":"10.1038","volume":"9","author":[{"given":"Min Ho","family":"Choe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yina","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Gu","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hoon","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-4515","authenticated-orcid":false,"given":"Jae-Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"698_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246\u2013257 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"698_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","volume":"15","author":"T Moroishi","year":"2015","unstructured":"Moroishi, T., Hansen, C. G. & Guan, K. L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 15, 73\u201379 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"698_CR3","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s00018-016-2412-x","volume":"74","author":"MH Kim","year":"2017","unstructured":"Kim, M. H. & Kim, J. Role of YAP\/TAZ transcriptional regulators in resistance to anti-cancer therapies. Cell Mol. Life Sci. 74, 1457\u20131474 (2017).","journal-title":"Cell Mol. Life Sci."},{"key":"698_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","volume":"158","author":"A Kapoor","year":"2014","unstructured":"Kapoor, A. et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158, 185\u2013197 (2014).","journal-title":"Cell"},{"key":"698_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","volume":"47","author":"L Lin","year":"2015","unstructured":"Lin, L. et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 47, 250\u2013256 (2015).","journal-title":"Nat. Genet."},{"key":"698_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.15252\/embj.201592081","volume":"35","author":"MH Kim","year":"2016","unstructured":"Kim, M. H. et al. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP\/TAZ activation. EMBO J. 35, 462\u2013478 (2016).","journal-title":"EMBO J."},{"key":"698_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrc3932","volume":"15","author":"S Lin","year":"2015","unstructured":"Lin, S. & Gregory, R. I. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer 15, 321\u2013333 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"698_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","volume":"20","author":"J Hayes","year":"2014","unstructured":"Hayes, J., Peruzzi, P. P. & Lawler, S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol. Med. 20, 460\u2013469 (2014).","journal-title":"Trends Mol. Med."},{"key":"698_CR9","first-page":"332","volume":"3","author":"P Magee","year":"2015","unstructured":"Magee, P., Shi, L. & Garofalo, M. Role of microRNAs in chemoresistance. Ann. Transl. Med. 3, 332 (2015).","journal-title":"Ann. Transl. Med."},{"key":"698_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nm.2577","volume":"18","author":"M Garofalo","year":"2011","unstructured":"Garofalo, M. et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 18, 74\u201382 (2011).","journal-title":"Nat. Med."},{"key":"698_CR11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccr.2009.10.014","volume":"16","author":"M Garofalo","year":"2009","unstructured":"Garofalo, M. et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 16, 498\u2013509 (2009).","journal-title":"Cancer Cell."},{"key":"698_CR12","doi-asserted-by":"crossref","first-page":"53558","DOI":"10.18632\/oncotarget.10669","volume":"7","author":"X Sun","year":"2016","unstructured":"Sun, X. et al. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR\/IGF-1R\/CRAF and inhibiting the MAPK and PI3K\/AKT signaling pathways. Oncotarget 7, 53558\u201353570 (2016).","journal-title":"Oncotarget"},{"key":"698_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/pcmr.12578","volume":"30","author":"L Koetz-Ploch","year":"2017","unstructured":"Koetz-Ploch, L. et al. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment. Cell Melanoma Res. 30, 328\u2013338 (2017).","journal-title":"Pigment. Cell Melanoma Res."},{"key":"698_CR14","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/j.bbadis.2016.07.017","volume":"1862","author":"HJ An","year":"2016","unstructured":"An, H. J. et al. Novel miR-5582-5p functions as a tumor suppressor by inducing apoptosis and cell cycle arrest in cancer cells through direct targeting of GAB1, SHC1, and CDK2. Biochim. Biophys. Acta 1862, 1926\u20131937 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"698_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cbf.3119","volume":"33","author":"CJ Lei","year":"2015","unstructured":"Lei, C. J. et al. Hsa-miR-132 inhibits proliferation of hepatic carcinoma cells by targeting YAP. Cell Biochem. Funct. 33, 326\u2013333 (2015).","journal-title":"Cell Biochem. Funct."},{"key":"698_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bbrc.2010.03.036","volume":"394","author":"AM Liu","year":"2010","unstructured":"Liu, A. M., Poon, R. T. & Luk, J. M. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem. Biophys. Res. Commun. 394, 623\u2013627 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"698_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000430358","volume":"37","author":"C Huang","year":"2015","unstructured":"Huang, C. et al. MiR-497 suppresses YAP1 and inhibits tumor growth in non-small cell lung cancer. Cell. Physiol. Biochem. 37, 342\u2013352 (2015).","journal-title":"Cell. Physiol. Biochem."},{"key":"698_CR18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/aps.2014.59","volume":"35","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3\u2032UTR. Acta Pharmacol. Sin. 35, 1207\u20131214 (2014).","journal-title":"Acta Pharmacol. Sin."},{"key":"698_CR19","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.18632\/oncotarget.3254","volume":"6","author":"G Tan","year":"2015","unstructured":"Tan, G. et al. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ. Oncotarget 6, 8676\u20138686 (2015).","journal-title":"Oncotarget"},{"key":"698_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont, S. et al. Role of YAP\/TAZ in mechanotransduction. Nature 474, 179\u2013183 (2011).","journal-title":"Nature"},{"key":"698_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/2043-9113-3-22","volume":"3","author":"CP Goswami","year":"2013","unstructured":"Goswami, C. P. & Nakshatri, H. PROGgene: gene expression based survival analysis web application for multiple cancers. J. Clin. Bioinforma. 3, 22 (2013).","journal-title":"J. Clin. Bioinforma."},{"key":"698_CR22","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1053\/j.gastro.2009.11.005","volume":"138","author":"JJ Smith","year":"2010","unstructured":"Smith, J. J. et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138, 958\u2013968 (2010).","journal-title":"Gastroenterology"},{"key":"698_CR23","doi-asserted-by":"publisher","first-page":"7642","DOI":"10.1158\/1078-0432.CCR-09-1431","volume":"15","author":"RN Jorissen","year":"2009","unstructured":"Jorissen, R. N. et al. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin. Cancer Res. 15, 7642\u20137651 (2009).","journal-title":"Clin. Cancer Res."},{"key":"698_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.canlet.2014.04.013","volume":"350","author":"Z Chen","year":"2014","unstructured":"Chen, Z. et al. MiRNA expression profile reveals a prognostic signature for esophageal squamous cell carcinoma. Cancer Lett. 350, 34\u201342 (2014).","journal-title":"Cancer Lett."},{"key":"698_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.cell.2013.12.043","volume":"156","author":"M Mori","year":"2014","unstructured":"Mori, M. et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell 156, 893\u2013906 (2014).","journal-title":"Cell"},{"key":"698_CR26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/1078-0432.CCR-11-1446","volume":"19","author":"M Mao","year":"2013","unstructured":"Mao, M. et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin. Cancer Res. 19, 657\u2013667 (2013).","journal-title":"Clin. Cancer Res."},{"key":"698_CR27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/0008-5472.CAN-11-2941","volume":"72","author":"H Yang","year":"2012","unstructured":"Yang, H. et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 72, 779\u2013789 (2012).","journal-title":"Cancer Res."},{"key":"698_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227\u2013235 (2012).","journal-title":"Cancer Discov."},{"key":"698_CR29","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1158\/0008-5472.CAN-13-3569","volume":"74","author":"S Song","year":"2014","unstructured":"Song, S. et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 74, 4170\u20134182 (2014).","journal-title":"Cancer Res."},{"key":"698_CR30","doi-asserted-by":"crossref","first-page":"53853","DOI":"10.18632\/oncotarget.10793","volume":"7","author":"JY Ho","year":"2016","unstructured":"Ho, J. Y. et al. Reduced miR-550a-3p leads to breast cancer initiation, growth, and metastasis by increasing levels of ERK1 and 2. Oncotarget 7, 53853\u201353868 (2016).","journal-title":"Oncotarget"},{"key":"698_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.canlet.2017.04.011","volume":"399","author":"C Ou","year":"2017","unstructured":"Ou, C. et al. MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer. Cancer Lett. 399, 53\u201363 (2017).","journal-title":"Cancer Lett."},{"key":"698_CR32","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1158\/0008-5472.CAN-11-1243","volume":"71","author":"J Villanueva","year":"2011","unstructured":"Villanueva, J., Vultur, A. & Herlyn, M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 71, 7137\u20137140 (2011).","journal-title":"Cancer Res."},{"issue":"W1","key":"698_CR33","doi-asserted-by":"publisher","first-page":"W460","DOI":"10.1093\/nar\/gkv403","volume":"43","author":"IS Vlachos","year":"2015","unstructured":"Vlachos, I. S. et al. DIANA-miRPathv3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 43(W1), W460\u2013W466 (2015).","journal-title":"Nucleic Acids Res."},{"key":"698_CR34","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/ncb2615","volume":"14","author":"K Tumaneng","year":"2012","unstructured":"Tumaneng, K. et al. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat. Cell Biol. 14, 1322\u20131329 (2012).","journal-title":"Nat. Cell Biol."},{"key":"698_CR35","doi-asserted-by":"publisher","first-page":"6667","DOI":"10.1158\/0008-5472.CAN-13-0888","volume":"73","author":"JS Kim","year":"2013","unstructured":"Kim, J. S., Kim, E. J., Oh, J. S., Park, I. C. & Hwang, S. G. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1. Cancer Res. 73, 6667\u20136678 (2013).","journal-title":"Cancer Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0698-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0698-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0698-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:59:47Z","timestamp":1671537587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0698-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-0698-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"26 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"640"}}